Reply to ‘Comment on: Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab’

Abstract

Another aspect of NVG prevention is represented by treating the patients with central/hemi-CRVOs in whom ocular neovascularization already has appeared but IOP still remains within normal limits (eg, the preglaucomatous stage of NVG 2 ). In such cases we administer IVB injections, topical steroids, and cycloplegics; unless the neovascularization subsides with these treatments, we promptly apply panretinal photocoagulation that may prevent or delay any developing of the intractable sightthreatening NVG.In conclusion, we believe that at a dose of 2.5 mg injected promptly before occurrence of neovascularization and IOP elevation, IVB offers a real benefit and promise for the prevention of NVG in patients with acute central/hemi-CRVOs. Early diagnosis and treatment with bevacizumab are required in order to maintain a good visual status and a satisfactory IOP control. Conflict of interestThe authors declare no conflict of interest. Author contributionsBoth authors (DC and MC) were involved in design and conduct of the study; collection, management, analysis and interpretation of the data; and preparation, review or approval of the manuscript.